MARKET

FLGT

FLGT

Fulgent Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.52
+0.99
+1.82%
After Hours: 55.40 -0.12 -0.22% 16:53 07/01 EDT
OPEN
54.44
PREV CLOSE
54.53
HIGH
55.84
LOW
54.19
VOLUME
173.87K
TURNOVER
0
52 WEEK HIGH
112.00
52 WEEK LOW
47.34
MARKET CAP
1.68B
P/E (TTM)
3.753
1D
5D
1M
3M
1Y
5Y
Fulgent Genetics, Inc. (FLGT) Dips More Than Broader Markets: What You Should Know
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $54.65, moving -0.35% from the previous trading session.
Zacks · 2d ago
Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $49.73, moving -0.4% from the previous trading session.
Zacks · 06/21 22:15
Is Fulgent Genetics (NASDAQ:FLGT) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 06/04 12:06
We Think Fulgent Genetics (NASDAQ:FLGT) Might Have The DNA Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Simply Wall St. · 05/19 11:04
--Piper Sandler Adjusts Fulgent Genetics' Price Target to $70 From $85, Reiterates Overweight Rating
MT Newswires · 05/16 07:04
--Oppenheimer Adjusts Fulgent Genetics Price Target to $112 From $123, Maintains Outperform Rating
MT Newswires · 05/04 11:15
Fulgent Genetics raises 2022 revenue guidance, but lowers income outlook
Fulgent Genetics (NASDAQ:FLGT) raised its 2022 revenue guidance to $660M (from $600M) but also lowered its full-year non-GAAP net income outlook to $6 per share (from $7). The genetic testing
Seekingalpha · 05/03 21:46
Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 21:25
More
No Data
Learn about the latest financial forecast of FLGT. Analyze the recent business situations of Fulgent Genetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FLGT stock price target is 91.00 with a high estimate of 112.00 and a low estimate of 70.00.
High112.00
Average91.00
Low70.00
Current 55.52
EPS
Actual
Estimate
1.272.543.815.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 296
Institutional Holdings: 13.06M
% Owned: 43.05%
Shares Outstanding: 30.33M
TypeInstitutionsShares
Increased
101
1.78M
New
36
455.39K
Decreased
65
773.44K
Sold Out
58
310.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+2.95%
Healthcare Providers & Services
+1.63%
Key Executives
Chairman/President/Chief Executive Officer/Director
Ming Hsieh
Chief Financial Officer
Paul Kim
Chief Operating Officer
Jian Xie
Chief Scientific Officer
Han Lin Gao
Independent Director
John Bolger
Independent Director
Linda Marsh
No Data
No Data
About FLGT
Fulgent Genetics, Inc. is a technology company, which offers COVID-19 testing services, molecular diagnostic testing services and comprehensive genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the patient care quality. The Company develops a technology platform, which offers a test menu. It performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. It also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.

Webull offers kinds of Fulgent Genetics Inc stock information, including NASDAQ:FLGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLGT stock methods without spending real money on the virtual paper trading platform.